Portage Biotech Competitors

Portage Biotech (NASDAQ:PRTG) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Portage Biotech and Cullinan Oncology, as reported by MarketBeat.

Cullinan Oncology has a consensus price target of $48.75, suggesting a potential upside of 76.63%. Given Cullinan Oncology's higher possible upside, analysts clearly believe Cullinan Oncology is more favorable than Portage Biotech.

Valuation & Earnings

This table compares Portage Biotech and Cullinan Oncology's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Portage Biotech and Cullinan Oncology's net margins, return on equity and return on assets.

Summary

Cullinan Oncology beats Portage Biotech on 2 of the 2 factors compared between the two stocks.

Portage Biotech (NASDAQ:PRTG) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Portage Biotech and Edgewise Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Portage Biotech and Edgewise Therapeutics, as provided by MarketBeat.com.

Edgewise Therapeutics has a consensus price target of $34.25, indicating a potential upside of 26.34%. Given Edgewise Therapeutics' higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Portage Biotech.

Valuation & Earnings

This table compares Portage Biotech and Edgewise Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Edgewise Therapeutics beats Portage Biotech on 2 of the 2 factors compared between the two stocks.

Portage Biotech (NASDAQ:PRTG) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Portage Biotech and Nurix Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for Portage Biotech and Nurix Therapeutics, as reported by MarketBeat.

Nurix Therapeutics has a consensus price target of $46.00, indicating a potential upside of 76.86%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Portage Biotech.

Profitability

This table compares Portage Biotech and Nurix Therapeutics' net margins, return on equity and return on assets.

Summary

Nurix Therapeutics beats Portage Biotech on 3 of the 3 factors compared between the two stocks.

Portage Biotech (NASDAQ:PRTG) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Profitability

This table compares Portage Biotech and Kinnate Biopharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Portage Biotech and Kinnate Biopharma's revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Portage Biotech and Kinnate Biopharma, as reported by MarketBeat.

Kinnate Biopharma has a consensus price target of $52.00, indicating a potential upside of 126.88%. Given Kinnate Biopharma's higher probable upside, analysts clearly believe Kinnate Biopharma is more favorable than Portage Biotech.

Summary

Kinnate Biopharma beats Portage Biotech on 2 of the 2 factors compared between the two stocks.

Connect Biopharma (NASDAQ:CNTB) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Connect Biopharma and Portage Biotech, as reported by MarketBeat.com.

Connect Biopharma currently has a consensus price target of $29.50, suggesting a potential upside of 82.10%. Given Connect Biopharma's higher possible upside, equities analysts clearly believe Connect Biopharma is more favorable than Portage Biotech.

Profitability

This table compares Connect Biopharma and Portage Biotech's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Connect Biopharma and Portage Biotech's gross revenue, earnings per share (EPS) and valuation.

Summary

Connect Biopharma beats Portage Biotech on 2 of the 2 factors compared between the two stocks.

Portage Biotech (NASDAQ:PRTG) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Portage Biotech and Silverback Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Portage Biotech and Silverback Therapeutics' revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Portage Biotech and Silverback Therapeutics, as reported by MarketBeat.

Silverback Therapeutics has a consensus target price of $50.25, indicating a potential upside of 79.59%. Given Silverback Therapeutics' higher probable upside, analysts plainly believe Silverback Therapeutics is more favorable than Portage Biotech.

Summary

Silverback Therapeutics beats Portage Biotech on 2 of the 2 factors compared between the two stocks.